C-X-C chemokine receptor type 5 (CXC-R5) also known as CD185 (cluster of differentiation 185) or Burkitt lymphoma receptor 1 (BLR1) is a G protein-coupled seven transmembrane receptor for chemokine CXCL13 (also known as BLC) and belongs to the CXC chemokine receptor family. It enables T cells to migrate to lymph node B cell zones. In humans, the CXC-R5 protein is encoded by the CXCR5gene.
The BLR1 / CXCR5gene is specifically expressed in Burkitt's lymphoma and lymphatic tissues, such as follicles in lymph nodes as well as in spleen. The gene plays an essential role in B cell migration. Through CXCL13 secretions B cells are able to locate the lymph node.
Additionally, some recent studies have suggested that CXCL13, though CXCR5, is capable of recruiting hematopoietic precursor cells (CD3− CD4+) which would cause the development of lymph nodes and Peyer's Patches.
Other studies highlight the role of CXCR5 in T cells, as they are unable to access B cell follicles without CXCR5 expression. This is a key step in the production of high affinity antibodies as B cells and T cells need to interact in order to activate the Ig class switch.
CXCR5 has been shown to be expressed on both CD4 and CD8 T cells, though it is often regarded as the defining marker for T Follicular Helper (Tfh) cells.
Recently, it was shown that CXCR5 overexpression in breast cancer patients highly correlates with lymph node metastases, and elevated CXCR5 expression may contribute to abnormal cell survival and migration in breast tumors that lack functional p53 protein. Minor allele of SNP rs630923, located in the area of CXCR5 gene promoter and associated with the risk of multiple sclerosis, is responsible for appearance of MEF2C-binding site resulted in reduced CXCR5 gene promoter activity in B-cells during activation, that could lead to decreased autoimmune response 
While chemokines and chemokine receptors have been thought to be involved in cancer development and maintenance, recently CXCR5 has come under investigation for its role in metastatic progression of prostate cancer. A recent study has indicated that prostate cancer tissue as well as cell lines express higher non-basal levels of CXCR5. Furthermore, the study found a correlation between the level of CXCR5 and Gleason score. CXCR5 location was additionally considered and higher Gleason scores correlated with nuclear CXCR5 while cytoplasmic and membrane CXCR5 correlated with benign and early prostate cancers.
^Dobner T, Wolf I, Emrich T, Lipp M (November 1992). "Differentiation-specific expression of a novel G protein-coupled receptor from Burkitt's lymphoma". European Journal of Immunology. 22 (11): 2795–9. doi:10.1002/eji.1830221107. PMID1425907.
^ abFörster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M (December 1996). "A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen". Cell. 87 (6): 1037–47. doi:10.1016/S0092-8674(00)81798-5. PMID8978608.
^ abJunt, Tobias; Fink, Katja; Förster, Reinhold; Senn, Beatrice; Lipp, Martin; Muramatsu, Masamichi; Zinkernagel, Rolf M.; Ludewig, Burkhard; Hengartner, Hans (2005-12-01). "CXCR5-dependent seeding of follicular niches by B and Th cells augments antiviral B cell responses". Journal of Immunology. 175 (11): 7109–7116. doi:10.4049/jimmunol.175.11.7109. ISSN0022-1767. PMID16301613.
^Hardtke, S. (2005-09-15). "Balanced expression of CXCR5 and CCR7 on follicular T helper cells determines their transient positioning to lymph node follicles and is essential for efficient B-cell help". Blood. 106 (6): 1924–1931. doi:10.1182/blood-2004-11-4494. ISSN0006-4971. PMID15899919.
^Chevalier N, Jarrossay D, Ho E, Avery DT, Ma CS, Yu D, Sallusto F, Tangye SG, Mackay CR (May 2011). "CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses". Journal of Immunology. 186 (10): 5556–68. doi:10.4049/jimmunol.1002828. PMID21471443.
^He R, Hou S, Liu C, Zhang A, Bai Q, Han M, Yang Y, Wei G, Shen T, Yang X, Xu L, Chen X, Hao Y, Wang P, Zhu C, Ou J, Liang H, Ni T, Zhang X, Zhou X, Deng K, Chen Y, Luo Y, Xu J, Qi H, Wu Y, Ye L (August 2016). "Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection". Nature. 537 (7620): 412–428. doi:10.1038/nature19317. PMID27501245.
^Biswas S, Sengupta S, Roy Chowdhury S, Jana S, Mandal G, Mandal PK, Saha N, Malhotra V, Gupta A, Kuprash DV, Bhattacharyya A (January 2014). "CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis". Breast Cancer Research and Treatment. 143 (2): 265–76. doi:10.1007/s10549-013-2811-8. PMID24337540.
Müller G, Lipp M (September 2001). "Signal transduction by the chemokine receptor CXCR5: structural requirements for G protein activation analyzed by chimeric CXCR1/CXCR5 molecules". Biological Chemistry. 382 (9): 1387–97. doi:10.1515/BC.2001.171. PMID11688722.
Schaerli P, Loetscher P, Moser B (December 2001). "Cutting edge: induction of follicular homing precedes effector Th cell development". Journal of Immunology. 167 (11): 6082–6. doi:10.4049/jimmunol.167.11.6082. PMID11714765.
Kim CH, Johnston B, Butcher EC (July 2002). "Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity". Blood. 100 (1): 11–6. doi:10.1182/blood-2001-12-0196. PMID12070001.
Battle TE, Yen A (October 2002). "Ectopic expression of CXCR5/BLR1 accelerates retinoic acid- and vitamin D(3)-induced monocytic differentiation of U937 cells". Experimental Biology and Medicine. 227 (9): 753–62. doi:10.1177/153537020222700906. PMID12324654.
Lisignoli G, Toneguzzi S, Piacentini A, Cattini L, Lenti A, Tschon M, Cristino S, Grassi F, Facchini A (January 2003). "Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N-acetylhexosaminidase release". Journal of Cellular Physiology. 194 (1): 71–9. doi:10.1002/jcp.10188. PMID12447991.
Chan CC, Shen D, Hackett JJ, Buggage RR, Tuaillon N (February 2003). "Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma". Ophthalmology. 110 (2): 421–6. doi:10.1016/S0161-6420(02)01737-2. PMID12578791.
Flynn G, Maru S, Loughlin J, Romero IA, Male D (March 2003). "Regulation of chemokine receptor expression in human microglia and astrocytes". Journal of Neuroimmunology. 136 (1–2): 84–93. doi:10.1016/S0165-5728(03)00009-2. PMID12620646.
Lisignoli G, Piacentini A, Toneguzzi S, Grassi F, Tschon M, Cristino S, Facchini A, Mariani E (2004). "Age-associated changes in functional response to CXCR3 and CXCR5 chemokine receptors in human osteoblasts". Biogerontology. 4 (5): 309–17. doi:10.1023/A:1026203502385. PMID14618028.
Aust G, Sittig D, Becherer L, Anderegg U, Schütz A, Lamesch P, Schmücking E (February 2004). "The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases". European Journal of Endocrinology. 150 (2): 225–34. doi:10.1530/eje.0.1500225. PMID14763921.
Steinmetz OM, Panzer U, Kneissler U, Harendza S, Lipp M, Helmchen U, Stahl RA (April 2005). "BCA-1/CXCL13 expression is associated with CXCR5-positive B-cell cluster formation in acute renal transplant rejection". Kidney International. 67 (4): 1616–21. doi:10.1111/j.1523-1755.2005.00244.x. PMID15780119.
Hu C, Xiong J, Zhang L, Huang B, Zhang Q, Li Q, Yang M, Wu Y, Wu Q, Shen Q, Gao Q, Zhang K, Sun Z, Liu J, Jin Y, Tan J (August 2004). "PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia". Cellular & Molecular Immunology. 1 (4): 280–94. PMID16225771.